- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 233/26 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes
Détention brevets de la classe C07D 233/26
Brevets de cette classe: 56
Historique des publications depuis 10 ans
6
|
5
|
3
|
2
|
7
|
5
|
4
|
2
|
2
|
0
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 461 |
10 |
B3ar Therapeutics, Inc. | 17 |
5 |
Merck Patent GmbH | 5850 |
3 |
F. Hoffmann-La Roche AG | 7923 |
2 |
Massachusetts Institute of Technology | 10019 |
2 |
Board of Regents, The University of Texas System | 5754 |
2 |
President and Fellows of Harvard College | 5952 |
2 |
The Board of Trustees of the University of Illinois | 2686 |
2 |
Alzheon, Inc. | 52 |
2 |
Arbutus Biopharma Corporation | 177 |
2 |
The Arizona Board of Regents on Behalf of the University of Arizona | 2145 |
2 |
H. Lee Moffitt Cancer Center and Research Institute, Inc. | 933 |
2 |
Kyushu University, National University Corporation | 1648 |
2 |
The Regents of the University of Colorado, a body corporate | 2627 |
2 |
Sumitomo Metal Mining Co., Ltd. | 1761 |
2 |
Agc, Inc. | 4760 |
2 |
Inspirna, Inc. | 38 |
2 |
University of Florida Research Foundation, Inc. | 3994 |
1 |
Board of Trustees of Michigan State University | 1178 |
1 |
Philera New Zealand Limited | 14 |
1 |
Autres propriétaires | 7 |